InSilicoTrials has entered a strategic partnership with HanchorBio Inc. to advance AI-driven clinical development for HCB101, HanchorBio's lead immunotherapy candidate.

Press release · HanchorBio

InSilicoTrials and HanchorBio have entered a strategic partnership to explore how AI-driven simulations and virtual patients could support the clinical development of HCB101. The initial work will focus on trial design for gastric cancer and assess whether external or simulated controls could reduce the number of patients needed in conventional control groups.